2.00
0.11 (5.54%)
| Penutupan Terdahulu | 1.90 |
| Buka | 1.88 |
| Jumlah Dagangan | 2,266,467 |
| Purata Dagangan (3B) | 1,778,426 |
| Modal Pasaran | 195,237,312 |
| Harga / Jualan (P/S) | 8.31 |
| Harga / Buku (P/B) | 18.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Mar 2026 |
| Margin Operasi (TTM) | -758.05% |
| EPS Cair (TTM) | -3.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 310.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 49.88% |
| Nisbah Semasa (MRQ) | 3.08 |
| Aliran Tunai Operasi (OCF TTM) | -208.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -103.52 M |
| Pulangan Atas Aset (ROA TTM) | -36.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -140.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Editas Medicine, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.70 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.33% |
| % Dimiliki oleh Institusi | 57.56% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 8.00 (Jones Trading, 300.00%) | Beli |
| Median | 5.75 (187.50%) | |
| Rendah | 3.50 (Chardan Capital, 75.00%) | Beli |
| Purata | 5.75 (187.50%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 2.00 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jones Trading | 10 Mar 2026 | 8.00 (300.00%) | Beli | 2.00 |
| Chardan Capital | 09 Mar 2026 | 3.50 (75.00%) | Beli | 2.00 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BURKLY LINDA | - | 2.04 | -749 | -1,528 |
| O'NEILL GILMORE NEIL | - | 2.04 | -5,394 | -11,004 |
| PARISON AMY | - | 2.04 | -474 | -967 |
| Jumlah Keseluruhan Kuantiti Bersih | -6,617 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -13,499 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 2.04 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BURKLY LINDA | Pegawai | 03 Mar 2026 | Jual (-) | 749 | 2.04 | 1,528 |
| PARISON AMY | Pegawai | 03 Mar 2026 | Jual (-) | 474 | 2.04 | 967 |
| O'NEILL GILMORE NEIL | Pegawai | 03 Mar 2026 | Jual (-) | 5,394 | 2.04 | 11,004 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Jan 2026 | Pengumuman | Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |